top of page
Article title: Genome sequencing reveals CCDC88A variants in malformations of cortical development and immune dysfunction
First author:Johanna Lehtonen
Journal: Human Molecular Genetics
Author of the abstract: Philippe Mertz

Nouvelle actinopathie avec manifestations neuro-développementales et dysimmunitaires associée aux variants de CCDC88A

Three key points to remember:

  1. Two new variants of CCDC88A have been identified in two full-term children born to unrelated parents of Finnish origin, who suffer from cortical malformations, microcephaly, and epilepsy. This gene encodes the protein girdin, which can bind to actin and acts as a regulator of the actin cytoskeleton.

  2. Their fibroblasts show qualitative and functional abnormalities of the actin cytoskeleton.

  3. This actinopathy is associated with immune disorders, including an associated immune deficiency, and probably also with inflammatory disorders (inflammatory colitis in one of the two patients).

Actinopathies are a group of rare genetic diseases in which abnormalities in the dynamics of the actin cytoskeleton disrupt various cellular functions, particularly in the immune and nervous systems. They are associated with complex clinical phenotypes, which may include manifestations such as malformations and dysmorphic syndrome, neurodevelopmental delay, manifestations such as primary immunodeficiency, or autoimmune and autoinflammatory manifestations.

The CCDC88A gene encodes the protein girdin, a protein capable of binding directly to actin and participating in the regulation of its functions. It acts as a multifunctional adapter essential for the organization of the actin cytoskeleton, PI3K-AKT signaling, cell migration, and the regulation of the balance between proliferation and migration. Girdin also interacts with many proteins, including EGFR, and is involved in the formation of the immunological synapse, autophagy, and vesicular trafficking.

In this study, the authors report on two patients, a brother and sister, born to two unrelated parents of Finnish origin, who suffered from cortical developmental malformations, postnatal microcephaly, severe epilepsy, profound intellectual disability, and increased susceptibility to infections. Whole genome sequencing revealed composite heterozygous variants of CCDC88A in both children, including a missense mutation (p.Asp310Ala) and an intragenic deletion of three exons (p.E508*), which had not been reported previously. Simple heterozygous carriage of these variants was detected in asymptomatic individuals in the family.


The family pedigree illustrates the segregation of the intragenic deletion and the missense variant (c.929A > C:p.Asp310Ala) identified in CCDC88A

Functional analysis of patients' fibroblasts has enabled the cellular consequences of girdin deficiency to be characterized for the first time. The mutated cells show increased proliferation, decreased migration, reduced cell size, disorganization of the actin cytoskeleton (elongated, aggregated, and poorly reticulated bundles), decreased focal adhesions, and perinuclear accumulation of endolysosomal organelles. These phenotypes were reproduced in fibroblast lines knocked out for CCDC88A by CRISPR-Cas9, confirming that this is an actinopathy associated with loss of girdin function.


Immunologically, girdin is mainly expressed by monocytes, macrophages, and dendritic cells, and less so by T lymphocytes. Patients showed marked susceptibility to respiratory infections, defective vaccine response, moderate B lymphopenia, reduced numbers of monocyte-like and plasmacytoid dendritic cells, and decreased regulatory T cells. One patient also had chronic inflammatory bowel disease diagnosed on the basis of compatible abdominal symptoms and elevated fecal calprotectin. Interestingly, girdin deficiency leads to a hyperreactive immune response by macrophages in the mouse model of dextran sodium sulfate-induced colitis (a model that also presents with a shortened colon and significant weight loss). These data support the existence of a combined immune deficiency affecting innate and adaptive immunity, and associated inflammatory manifestations.


CCDC88A had already been implicated in neurodevelopmental encephalopathies caused by homozygous truncating variants, but this is the first time that an immune dysfunction phenotype has been authenticated in patients carrying mutations in this gene. It is also the first study to demonstrate, through functional approaches on primary cells and CRISPR models, that CCDC88A variants induce true immunoactinopathy.



 
 
 
Article title: Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX
First author: Vincent Jachiet
Journal: Blood
Author of the abstract: Philippe Mertz

 Efficacité et tolérance de l’azacitidine dans le syndrome VEXAS : données rétrospectives de la cohorte française FRENVEX

Three key points to remember:

  1. Azacitidine is an effective treatment option for VEXAS syndrome even without associated myelodysplasia, with simultaneous effects on inflammation, cytopenias, and the UBA1 clone.

  2. The response is often delayed and requires prolonged exposure (≥6 cycles) before evaluation. Adverse effects, particularly infectious ones, occur mainly in the first 3 cycles of treatment. Discontinuation of AZA leads to relapse in the majority of cases, suggesting a suspensive rather than curative effect.

  3. Molecular monitoring (UBA1 VAF) allows for objective assessment of clonal response and could become a biomarker for monitoring this disease.


VEXAS syndrome is an acquired monogenic autoinflammatory disease associated with somatic mutations in the UBA1 gene. Patients present with a wide spectrum of severe inflammatory manifestations and cytopenias, which may be associated with myelodysplastic syndrome (MDS). Treatment is mainly based on corticosteroids, with frequent corticosteroid dependence despite associated sparing therapy with targeted therapies (anti-IL-6, anti-JAK, etc.) that have inconsistent efficacy. Azacitidine (AZA), a hypomethylating agent used in MDS, has shown potential in VEXAS, but published data remain limited.

This is a retrospective multicenter study conducted in France by the FRENVEX group, including 88 patients with genetically confirmed VEXAS who received at least one cycle of AZA between 2009 and 2024.


In this study, inflammatory response was defined as both clinical and biological improvement in systemic manifestations, including reduction in inflammatory symptoms and sustained decrease in biological markers such as CRP. The hematologic response followed the 2018 International Working Group criteria for MDS and corresponded to a significant improvement in cytopenias, including an increase in hemoglobin, platelets, or neutrophils, or a reduction in transfusion requirements. Finally, the molecular response was established on the basis of at least a 25% reduction in the mutational burden (VAF) of the UBA1 variant, assessed by targeted sequencing during treatment. Treatment side effects were described according to the Common Terminology Criteria for Adverse Events (version 5.0).

Inflammatory, hematological, and molecular responses were evaluated, as well as tolerance, regardless of the presence of associated MDS (present in 80%).


The main results of this study show:

  • A partial or complete inflammatory response observed in 61% of patients (41% at 6 months, 54% at 12 months). The median response time was sometimes delayed (>6 cycles).

  • A hematological response with improvement in hemoglobin in 65% and platelet count in 77%, with clinical benefit in terms of cytopenias and transfusion requirements.

  • A molecular response with at least a 25% reduction in UBA1 mutation burden was observed in 65% of patients, correlating with the clinical response.

  • Severe adverse events (grade III and IV) occurred in 60% of patients, mainly infections (34%) and cytopenias (36%), occurring predominantly in the first 3 cycles.

  • 75% of patients relapse after stopping AZA (median duration of treatment-free period of 3.1 years), but resumption of treatment is effective in 80% of cases.


This study supports the use of AZA as first-line treatment in patients with VEXAS syndrome and severe cytopenias, or as second-line treatment in cases of failure of anti-inflammatory biotherapies, even in the absence of associated MDS. Treatment-related adverse effects, particularly infections, appear to occur mainly during the first 3 cycles of treatment. Prospective studies are needed to confirm its positioning and optimize the therapeutic strategy.

 
 
 

First author : Ozen S

Review: Annals of the Rheumatic Diseases

Reference: Ann Rheum Dis. 2025 Apr 9:S0003-4967(25)00084-6

Link to pubmed: EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update - PubMed

Recommandations approuvées par l’EULAR et la PReS pour la FMF

2024 European Recommendations on Familial Mediterranean Fever (FMF) – Summary:


Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide. Due to its clinical and genetic variability, specialized management is essential. In 2024, the EULAR and PReS societies updated their guidelines.


General Principles:

  • FMF requires specialist expertise for both diagnosis and management.

  • The primary goal is complete control of inflammation, including subclinical inflammation, to prevent complications such as AA amyloidosis.

  • Lifelong treatment is necessary, with strict adherence, primarily based on daily colchicine therapy.

  • Care should be patient-centered, aiming to preserve quality of life.


Key Recommendations:

  • Colchicine should be initiated as soon as a clinical diagnosis is made.

  • The dosage must be tailored to tolerance and adherence (single or divided daily doses).

  • If symptoms persist or subclinical inflammation remains, the dose should be increased within recommended limits (maximum 2 mg/day in children, 3 mg/day in adults).

  • If colchicine fails despite good adherence, interleukin-1 blockers (anakinra, canakinumab) are recommended.

  • Chronic musculoskeletal manifestations may require additional treatments (DMARDs, biologics).

  • Regular monitoring (clinical, biological, toxicity, adherence) is essential.

  • Colchicine should be continued during pregnancy and breastfeeding.

  • During acute attacks, colchicine should be maintained at the same dose, with symptomatic treatment added (e.g., NSAIDs).

  • A minimum core set of assessment criteria is proposed: attack frequency, quality of life, biological markers (CRP, SAA).


Quality indicators, clinical priorities (especially adherence), and implementation strategies are provided to harmonize care across centers.



 
 
 
bottom of page